STAT+: ARCH-launched Neumora stops depression program

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Let’s get straight to the news today.

The need-to-know this morning

  • Moderna said Ester Banque joined the company as chief commercial officer. She was formerly president of U.S. operations for Zoetis. Moderna President Stephen Hoge has also been given an expanded role overseeing several of the company’s drug development programs.

New AI model aims to improve trial enrollment

The biotech Verge Labs today released a new AI model that it says will help determine which patients will respond to treatment better, leading to fewer people dropping out while also increasing the statistical power of a trial.

Continue to STAT+ to read the full story…

Turning Rejection Into a Roadmap: Advice for the Next Generation of Mental Health Leaders

A Conversation with Tom Osborn, Founder of Africa’s Largest Mental Health Provider Shamiri Institute

Aaliyah Nadirah Madyun, program director at the Stavros Niarchos Foundation (SNF) Global Center for Child and Adolescent Mental Health at the Child Mind Institute, recently sat down with Tom Osborn, founder of the Shamiri Institute and an International Advisory Board member at the SNF Global Center. They discussed Osborn’s remarkable journey as a young entrepreneur.

At just 18, while studying at Harvard University, Osborn founded the Shamiri Institute, which has since grown into Africa’s largest youth mental health provider — now reaching over 100,000 young people annually and having trained and employed more than 3,000 providers. In this candid conversation, Osborn shares hard-won lessons on resilience, mentorship, and well-being. He offers advice to the SNF Global Center’s Youth Council members — many of whom are launching their own mental health initiatives in communities across Greece, Brazil, South Africa, and beyond.

AM: You founded Shamiri when you were just 18. Many members of our SNF Global Center Youth Councils are now launching their own mental health organizations. What advice would you give them?

TO: I think these past three to five years post-COVID have been quite good for mental health. There’s just more dialogue, more conversation. It’s maybe one of the best times to start working in mental health. There is a big space for young people to be leaders. On the other hand, it’s also very difficult.

AM: What kind of difficulties can young people expect to encounter?

TO: It’s very difficult for a few reasons. We normally start this work because we have a lot of passion, enthusiasm, and commitment to the cause. But that is not the day-to-day of being a social entrepreneur. It’s convincing people to partner with you, to fund you, etc., which is a completely different skill set to learn. And the second part is getting a level of comfort with failure. Because the reality is, on average, nine out of ten doors that you try to open will not open; especially when you are starting. For example, if you’re in Brazil and there are 100 other young people trying to start something, there is a finite pool of opportunities and resources. So, when you are starting, part of the initial process requires you to develop resilience and a growth mindset.

AM: Could you speak about the role mentorship has played in your journey, and how young entrepreneurs can leverage mentorship to navigate the challenges of building something from the ground up?

TO: Mentorship is really crucial. Finding folks — researchers, practitioners, or just folks in the community — who can help provide guidance as you build the skills you need to be an effective entrepreneur.

AM: How would you recommend young people go about finding a mentor? It seems like that ability, identifying and cultivating a mentoring relationship, might be a skill set in itself.

TO: In my experience, there are three pathways. In many countries we have what we call accelerators, which look for young people who literally have an idea and enthusiasm, and then take them through 10–16 weeks of bootcamp where they can learn the skills to develop their idea. So, that’s one pathway. The second pathway, which really worked for me but may sound intimidating, is direct outreach to folks who have done something similar. So, you can do some research. It doesn’t have to even be related to mental health. It can be education or some broader thing. But find someone who has built something that you admire. You will be surprised how many people are willing to support and pay it forward, because we all have benefited from the help of someone else. I created an Excel spreadsheet with a list of people who I looked up to, and I reached out to them on LinkedIn. Sometimes you can even find their email. Some people said “no”, but if you reach out to 10 or 20 people, some people will talk to you. And the third pathway is . . . increasingly we have a lot of resources like the SNF Global Center Youth Councils and international organizations that deal with mental health. You can join these organizations to expand your network.

AM: Could you share your story with us and tell us how you got started?

TO: I started when I was in University as part of a research project I was doing when I was studying psychology. I needed to do something for my thesis and in the process of doing that I applied to an accelerator. I also went to my professor and asked him, ‘Do you know anyone who could connect me with?’ In fact, he helped me write my first grant and gave me the opportunity to learn those entrepreneurial skills.

AM: Starting at such a young age, one can imagine that you must have encountered many challenges and setbacks. What were the key lessons you took away from that growth period?

TO: The reality of this work, and not to discourage people but to give a factual picture, is that there are more setbacks than there are wins. Part of the process is that you learn from the setbacks. I can give you an example of some of my own setbacks. In my first year of doing this, we tried to raise money. We applied for grants, sent out proposals, etc.; but we couldn’t raise any money. So, what I did after getting the rejection is I would email and ask, “Do you have any feedback for us about why we didn’t get the funding?” or “Can we jump on a call so you can explain what we can do better?” What I learned from that was the way I was communicating what we were doing made sense in my mind, but I wasn’t putting myself in the shoes of the person who was reviewing the proposal. I only have five to ten minutes of someone’s time. So, how can I really simplify my message? For example, my first proposal was, “Shamiri does task-shifting mental health interventions for adolescent depression, anxiety, etc.” If you are in the field, you maybe get it. But if you are somebody who is just reading grants on mental health education, you don’t really get it. Now we say, “Shamiri means thrive and we enable young people to thrive.” So that invites people to ask how we’re helping people to thrive.

AM: What is another setback that surprised you?

A second example of a failure is getting buy-in from the beneficiaries that we were trying to work with. I thought, “We have this great idea, we’ve done this research, and it works. We’re going to go to schools and they’re going to be like, ‘This is great! Come work with us.’ Teachers are going to want to work with us.” But actually, in our first three years we were trying to work with 25,000 students and we ended up working with only 1,000 students. We really struggled with getting people to sign up. The lesson from that was we were thinking more from the idea this was our product, rather than thinking, “What is the problem that I am trying to solve for this person?” To give a concrete example, there are three people we need to get buy-in from: young people in schools, teachers, and parents. Just having a great product does not mean that people are going to use it. You need to figure out what the problem is. How can I solve it? How do I communicate this to users?

AM: I can imagine that dealing with failures and setbacks is extremely hard, especially for a young person. What would you say to a young person who is currently experiencing this?

TO: Finding ways to stay grounded and healthy from a well-being perspective is really crucial. Identify what matters to you and connect with those things. And ideally if you can find a way to build a routine around that, it could help. Doing this work takes a big toll. If you don’t find ways to ground yourself and get the energy to continue with this, you may burn out.

AM: Do you have some final words for our Youth Council members and other young people reading this?

TO: Those closest to the problem are those closest to the solution. I am from Kenya, which is a really young country. The median age is 19 and 70 percent of the population is under 30. If we are to solve some of these pressing problems, including mental health, those solutions are going to have to come from young people.

The post Turning Rejection Into a Roadmap: Advice for the Next Generation of Mental Health Leaders appeared first on Child Mind Institute.

Assessment of tenecteplase target-associated pathogenic mechanisms underlying depression in acute ischemic stroke patients: insights from artificial intelligence-driven multi-omics analysis and in vitro validation

BackgroundAs a first-line treatment for acute ischemic stroke (AIS), tenecteplase (TNK) can cause adverse effects, such as depression, in AIS patients.ObjectiveThis study aims to elucidate the TNK target-related pathogenic mechanisms underlying major depressive disorder (MDD) in AIS patients.MethodsBy analyzing six public peripheral blood bulk datasets from AIS and MDD patients using integrative bioinformatics methods (limma, non-negative matrix factorization (NMF), and machine learning), we identified TNK target-associated molecular subgroups and diagnostic models for MDD and AIS patients, respectively. Next, a hub gene involved in the pathogenesis of both MDD and AIS was identified, and its corresponding molecular characteristics were analyzed in the peripheral blood bulk profiles of MDD and AIS patients. In addition, to gain a deeper understanding of the molecular implications of the hub gene involved in the pathogenesis of MDD in AIS, we performed disease ontology (DO) analysis and virtual cell knockout (KO) of the hub gene using public AIS mouse brain single-cell datasets. Furthermore, a deep learning pipeline (DrugReflector) model and molecular docking were used to identify MDD-preventive therapeutic agents for AIS patients based on MDD and AIS public blood bulk data. Finally, the expression pattern of the hub gene was also evaluated in MDD and AIS cell models.ResultsMyeloperoxidase (MPO) can be considered an upregulated TNK target-associated gene involved in the pathogenesis of MDD in AIS patients, and BRD-K11973162 can be considered an MDD-preventive therapeutic candidate for AIS patients after TNK treatment.ConclusionOur study is the first to identify MDD-associated diagnostic and therapeutic candidates for AIS patients after TNK treatment, providing a novel strategy for their clinical management.

Multimodal behavioral phenotyping for depressive-spectrum classification and severity estimation using eye tracking, facial behavior, and transcript-derived language

IntroductionDepression assessment remains largely dependent on symptom reports and clinician judgment, while objective tools for depressive-spectrum stratification and severity estimation remain limited. Existing digital and multimodal depression-detection studies often focus on binary case-control classification, handle missing modalities incompletely, provide limited calibration assessment, and rarely combine depressive-spectrum classification with continuous symptom-severity estimation. We therefore developed a quality-aware multimodal framework integrating eye tracking, facial behavior, and transcript-derived language for classification across normal control (NC), subthreshold depression (SD), and major depressive disorder (MDD), together with prediction of 17-item Hamilton Depression Rating Scale (HAMD-17) severity.MethodsA total of 186 participants completed a controlled task battery including interview, emotional reading, free viewing with verbal description, fixation, gaze orienting, smooth pursuit, prosaccade, and antisaccade tasks. Eye-tracking, facial-video, and transcript-derived language data were converted into modality-specific features. Baseline-3 combined modality-specific encoders, quality-aware gated fusion, and joint classification-regression learning under a nested repeated-resampling framework with explicit missing-modality handling. Baseline-3+ further incorporated Transformer-based cross-modal interaction and uncertainty-based dynamic task weighting. Performance was evaluated on held-out outer-loop test sets after temperature scaling. Interpretability analyses included gate profiling, selective prediction, SHAP, Integrated Gradients, and counterfactual analysis.ResultsBaseline-3+ showed the most favorable classification and calibration profile, with accuracy, balanced accuracy, and F1-macro approaching 0.90 across both classification routes and lower expected calibration error than Baseline-3. For severity estimation, the improvement was route-dependent and mainly reduced the regression disadvantage observed under the hierarchical route. Misclassification was concentrated near the SD boundary. Interpretability analyses showed stable quality-aware modality reweighting, with facial features providing the dominant signal, complemented by eye tracking and smaller but meaningful language contributions.DiscussionThis framework addresses key limitations of prior binary and incompletely calibrated depression-detection models by jointly supporting depressive-spectrum classification, severity estimation, missing-modality handling, calibrated prediction, and individual-level interpretation. Its most plausible role is to augment clinical assessment, particularly for boundary states such as SD.

Generative AI for pre-consultation mental health triage in disorders of gut-brain interaction

Disorders of gut-brain interaction (DGBI) are common, disabling, and frequently accompanied by anxiety, depressive symptoms, sleep disturbance, symptom-related fear, and repeated health care use. In routine gastroenterology practice, these problems are often recognized late, after fragmented histories, multiple visits, and avoidable investigations. Recent work on generative artificial intelligence (GenAI) and conversational systems suggests a narrower and more practical clinical use case than autonomous diagnosis: supervised pre-consultation triage. We propose that DGBI is a suitable setting for this approach because triage depends on integrating symptom narratives, prior investigations, alarm features, and psychosocial context rather than on a single test result. A GenAI-enabled intake tool could summarize patient-entered histories, incorporate brief distress screening and symptom diaries, flag possible medical or psychiatric escalation, and help route patients toward standard gastroenterology review, integrated psychogastroenterology, dietetic input, or urgent assessment. Its value would lie in making the first consultation more efficient and more clinically informed, not in replacing specialist judgment. For such systems to be acceptable, five conditions are essential: a narrowly defined triage task, multidomain but proportionate data collection, explicit rules for medical and psychiatric escalation, clinician review before action, and prospective evaluation across workflow, safety, equity, and patient acceptability. DGBI offers a realistic opportunity to develop GenAI tools that are useful precisely because they are constrained, auditable, and embedded in multidisciplinary care.

From digital access to social connectedness: the digital divide, bonding social capital, and depressive symptoms among older adults in China

IntroductionAs population aging and digital transformation continue simultaneously in China, the digital divide among older adults has become an increasingly important social issue. This study examines the associations between multiple dimensions of the digital divide and depressive symptoms among older adults, as well as the potential role of bonding social capital.MethodsDrawing on three waves of data from the China Family Panel Studies (CFPS, 2018–2022), this study employs two-way fixed effects models and mediation analyses to examine the relationships between digital access, digital usage, digital outcomes, and depressive symptoms among older adults. Robustness checks were further conducted using propensity score matching (PSM), sample restriction adjustments, and replacement of the dependent variable.ResultsInternet access was significantly associated with lower levels of depressive symptoms among older adults (p < 0.05). Compared with non-Internet users, entertainment-oriented, instrument-oriented, and mixed Internet use were all significantly associated with lower depressive symptoms (all p < 0.05). Digital outcomes were also negatively associated with depressive symptoms (p < 0.01). Bonding social capital showed significant indirect pathways linking all dimensions of the digital divide and depressive symptoms, with mediating proportions ranging from 5.95% to 26.67%. Period heterogeneity analyses further indicated that the associations remained generally stable before and during the COVID-19 period, although mixed Internet use exhibited a significant structural difference across periods (p = 0.036).DiscussionThe findings suggest that the digital divide is closely associated with the mental well-being of older adults, while bonding social capital constitutes an important social pathway linking digital engagement and psychological health. Policy efforts should move beyond technological access toward broader digital empowerment and the construction of a more inclusive digital society for aging populations.

Evaluation of Depression Screening Methods Administered by Registered Nurses in Chronic Hemodialysis Patients

Conditions: Depressive Disorders; End-stage Chronic Kidney Disease Treated With Hemodialysis

Interventions: Other: evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses

Sponsors: Centre Hospitalier Annecy Genevois; GIRCI Auvergne Rhone-Alpes; SFNDT – Société Francophone de Néphrologie, Dialyse et Transplantation

Not yet recruiting